Ibogaine Research Timeline: 1901 to 2026

Ibogaine research did not begin with the 2024 Stanford veteran study, and it did not begin with Howard Lotsof in 1962 either. The alkaloid was isolated from iboga root bark in 1901, sold as a French tonic for decades, banned in the United States, studied and then shelved by the National Institute on Drug Abuse, and kept alive for thirty years by case reports and observational studies before any institution with a large budget took a second look.

Most summaries of the evidence jump straight to the newest headline. Reading the studies in order explains why the evidence looks the way it does today: why there is still no completed placebo-controlled trial, why almost all human data comes from observational work in Mexico, New Zealand, Brazil, and the Caribbean, and why cardiac safety dominates every modern protocol. Our ibogaine research hub summarizes the findings by condition; this article puts them on a timeline.

Where Did Ibogaine Research Start? (1901 to the 1960s)

Ibogaine comes from Tabernanthe iboga, a shrub of West Central Africa used in the Bwiti initiation ceremonies of Gabon. Western chemistry caught up in 1901, when Dybowski and Landrin isolated the alkaloid from the root bark and gave it the name it still carries. If you need the basics before the history, start with what is ibogaine and come back.

For the first half of the twentieth century, ibogaine was a pharmaceutical curiosity rather than an addiction treatment. In France it was sold under the brand name Lambarène as a low-dose stimulant for fatigue and convalescence, from the late 1930s until the product was withdrawn in the 1960s. Nobody involved was thinking about opioids.

The addiction story begins in 1962 with Howard Lotsof, a nineteen-year-old heroin user in New York who took ibogaine for its psychoactive effects and noticed afterward that he was not in withdrawal and did not want heroin. He gave it to friends who used heroin and reported that several of them stopped. That anecdote is the seed of everything that followed. It was an observation, not evidence, and Lotsof spent the rest of his life trying to close that gap.

The regulatory door closed quickly. The United States placed ibogaine under federal control with the other hallucinogens in 1967 and listed it as a Schedule I substance under the Controlled Substances Act in 1970. Legal human research in the country became difficult, and the center of gravity shifted abroad, where it has largely stayed.

What Did the First Formal Studies Find? (1980s and 1990s)

Lotsof's 1985 U.S. patent, "Rapid method for interrupting the narcotic addiction syndrome," was the first formal claim that ibogaine could treat opioid dependence. Additional patents for cocaine, alcohol, nicotine, and poly-drug dependence followed. Through the late 1980s and early 1990s, Lotsof and Dutch addiction self-help groups treated people informally in the Netherlands, generating the first modern case histories and, tragically, some of the first documented fatalities.

The animal work arrived in parallel. Stanley Glick's laboratory at Albany Medical College showed in the early 1990s that a single dose of ibogaine reduced morphine and cocaine self-administration in rats, with effects that outlasted the presence of the drug in the body. Pharmacology labs mapped a receptor profile unlike any existing medication, touching opioid, NMDA, serotonin, and nicotinic receptors at once. In 1993, a Johns Hopkins study reported damage to Purkinje cells in the rat cerebellum at high doses, a finding that would shadow the field for the next decade and became a central reason for institutional caution.

The National Institute on Drug Abuse began a preclinical evaluation program in 1991, and in 1993 the FDA approved a Phase I safety study at the University of Miami under Deborah Mash. Then the funding stopped.

In 1995 a NIDA review meeting declined to support clinical trials, citing safety concerns and the reluctance of pharmaceutical partners. Mash moved her clinical work to St. Kitts, and the mid-1990s also produced 18-methoxycoronaridine, a synthetic analog designed by Glick and chemist Martin Kuehne to keep the anti-addictive effects and drop the cardiac and hallucinogenic ones.

The lesson of this era is structural. The one time ibogaine was close to a conventional development path, it lost institutional support before a single controlled human trial was run. Everything published in the next twenty years had to work around that absence.

What Did Case Series and Observational Studies Add? (1999 to 2018)

1999: the first peer-reviewed case series

Kenneth Alper, Lotsof, and colleagues published 33 cases of acute opioid withdrawal treated with ibogaine in the American Journal on Addictions. Most patients showed resolution of withdrawal signs without further drug seeking over the following days. It was the first peer-reviewed human series, and it was retrospective and uncontrolled.

2005: the GDNF mechanism

Dorit Ron's group reported in the Journal of Neuroscience that ibogaine increases glial cell line-derived neurotrophic factor, or GDNF, in the midbrain, and that GDNF mediated the drug's effect on alcohol consumption in rodents. That single mechanism paper is the origin of today's interest in ibogaine for Parkinson's, since GDNF supports the dopamine neurons that Parkinson's disease destroys.

2008: research trails practice

Alper, Lotsof, and Charles Kaplan described "the ibogaine medical subculture" in the Journal of Ethnopharmacology, estimating that several thousand people had taken ibogaine outside conventional medical settings and that use had grown roughly fourfold in five years. Research was now trailing practice.

2012: the fatality review

Alper, Stajić, and Gill reviewed 19 fatalities temporally associated with ibogaine between 1990 and 2008 in the Journal of Forensic Sciences. Pre-existing heart disease and concurrent drug use were the recurring themes, and there was no evidence of a characteristic neurotoxic syndrome. This paper is why cardiac screening, not cerebellar damage, became the safety conversation.

2014: ibogaine inside a treatment program

Eduardo Schenberg's group in Brazil published a retrospective study of 75 patients treated with ibogaine alongside psychotherapy in the Journal of Psychopharmacology, one of the first to look at ibogaine as part of a treatment program rather than a single event.

2015: the heart, and noribogaine

Xaver Koenig and Karlheinz Hilber published "The anti-addiction drug ibogaine and the heart: a delicate relation," pulling together the laboratory evidence that ibogaine and noribogaine block the hERG potassium channel and prolong the QT interval. Around the same time, first-in-human studies of noribogaine in New Zealand established the metabolite's safety profile in healthy volunteers and in opioid-dependent patients.

2018: three observational cohorts in one year

Two were sponsored by the Multidisciplinary Association for Psychedelic Studies: Thomas Kingsley Brown and Alper followed 30 participants treated in Mexico for twelve months, and Geoff Noller's team followed 14 participants in New Zealand over the same period. Mash and colleagues published outcomes from 191 people treated for opioid and cocaine dependence at the St. Kitts clinic in Frontiers in Pharmacology.

All three reported reduced use and withdrawal severity, and all three shared the limits of their design: self-selected participants, no control group, and loss to follow-up.

By 2018 the pattern was set. Ibogaine had a plausible mechanism, a consistent signal in uncontrolled human studies, a well-characterized cardiac risk, and no randomized trial.

Where Does Ibogaine Research Stand Today? (2020 to 2026)

The current era is defined by money and institutions finally re-entering the field. In 2020 David Olson's laboratory at UC Davis reported tabernanthalog in Nature, a non-hallucinogenic ibogaine analog that reduced alcohol and heroin seeking in rodents without the cardiac liability, and several companies have since built programs around ibogaine itself, noribogaine, and designed analogs.

In 2023 Kentucky's opioid settlement commission proposed committing $42 million to ibogaine research, the first serious public funding proposal in the United States. It was shelved after a change in state leadership, but it moved the idea from fringe to legislature.

In January 2024, Nolan Williams's group at Stanford published the study most people now cite first. Thirty U.S. special operations veterans with traumatic brain injury were treated at a Mexican clinic with a magnesium-ibogaine protocol, and the team reported large improvements in disability, PTSD, depression, and anxiety at one month, with no serious adverse events reported, in Nature Medicine.

It remains an open-label study with no placebo arm, and its authors said so, but it was the first ibogaine paper from a major U.S. academic center in a top-tier journal.

In 2025 Texas authorized $50 million for a public-private ibogaine consortium intended to fund FDA-track clinical trials, the largest single commitment the field has seen. Whether that funding produces a completed randomized trial by the end of the decade is the question that will define the next entry on this timeline.

What Has Ibogaine Research Still Not Answered?

• Controlled efficacy: no randomized, placebo-controlled trial of ibogaine for opioid use disorder has been completed. A Dutch open-label safety study published in Addiction in 2022 documented QTc prolongation and ataxia across its small cohort, a reminder that even careful modern protocols carry measurable risk. Blinding a drug with a twelve-hour psychoactive effect is a genuine methodological problem, not an excuse, and it has to be solved rather than waved away.

• Dose and formulation: Studies have used purified hydrochloride, total alkaloid extract, and root bark at widely varying doses. Comparing outcomes across them is guesswork.

• Who is represented: The published cohorts are predominantly male, predominantly opioid-dependent, and predominantly under fifty. Women, older adults, and people with stimulant or alcohol dependence are thinly studied.

• Long-term outcomes: Twelve months is the longest follow-up in the observational literature, and dropout rates over that year are substantial.

• Comparison to standard care: No study has compared ibogaine against buprenorphine or methadone maintenance, which is the comparison a regulator and an insurer will eventually demand.

• The Parkinson's hypothesis: The GDNF mechanism is real in rodents. Whether it translates to human dopamine neurons at tolerable doses is unstudied.

How to Use the Ibogaine Research Timeline

The practical value of this history is in the questions it lets you ask. When a clinic tells you its approach is "backed by research," ask which era and which study type: a 1990s rat study, a 2018 observational cohort, and the 2024 veteran trial support very different claims. When a website quotes a success rate, ask whether it comes from a controlled study, because as of 2026 none exists. And when someone dismisses ibogaine because "the government rejected it," remember that the rejection in 1995 was a funding decision made before the modern evidence was collected.

Ibogaine research is sixty years past Lotsof's observation and, for the first time, funded to finish the job. Until it does, the strongest position for a patient or a family member is the one this timeline supports: informed, cautious, and specific. The Ibogaine Treatment Guide exists to keep that information current, independent, and free of clinic marketing. Start with the research hub, then use the safety and screening guides before you speak to any provider.

This article is educational and does not constitute medical advice. Ibogaine carries serious cardiac risks and should only be considered under qualified medical supervision.